Literature DB >> 33070664

Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension.

Carmine Savoia1,2, Emanuele Arrabito1, Rosa Parente1, Carmine Nicoletti, Luca Madaro2, Allegra Battistoni1, Antonio Filippini2, Ulrike M Steckelings3, Rhian M Touyz4, Massimo Volpe1,5.   

Abstract

Angiotensin (1-7) production increases during AT1R (angiotensin type-1 receptor) blockade. The contribution of Ang (1-7) (angiotensin [1-7]) and its receptor (MasR) to the favorable effect of angiotensin receptor blockers on remodeling and function of resistance arteries remains unclear. We sought to determine whether MasR contributes to the improvement of vascular structure and function during chronic AT1R blockade. Spontaneously hypertensive rats were treated with Ang (1-7) or olmesartan ± MasR antagonist A-779, or vehicle, for 14 days. Blood pressure was measured by tail cuff methodology. Mesenteric arteries were dissected and mounted on a pressurized micromyograph to evaluate media-to-lumen ratio (M/L) and endothelial function. Expression of MasR and eNOS (endothelial nitric oxide synthase) was evaluated by immunoblotting, plasma nitrate by colorimetric assay, and reactive oxygen species production by dihydroethidium staining. Independently of blood pressure, olmesartan significantly reduced M/L and improved NO bioavailability, A-779 prevented these effects. Likewise, Ang (1-7) significantly reduced M/L and NO bioavailability. MasR expression was significantly increased by Ang (1-7) as well as by olmesartan, and it was blunted in the presence of A-779. Both Ang (1-7) and olmesartan increased eNOS expression and plasma nitrite which were reduced by A-779. Superoxide generation was attenuated by olmesartan and Ang (1-7) and was blunted in the presence of A-779. These MasR-mediated actions were independent of AT2R activation since olmesartan and Ang (1-7) increased MasR expression and reduced M/L in Ang II (angiotensin II)-infused AT2R knockout mice, independently of blood pressure control. A-779 prevented these effects. Hence, MasR activation may contribute to the favorable effects of AT1R antagonism on NO bioavailability and microvascular remodeling, independently of AT2R activation and blood pressure control.

Entities:  

Keywords:  angiotensin receptor blockers; angiotensin receptors; angiotensins; nitric oxide; oxidative stress; resistance arteries; vascular remodeling

Year:  2020        PMID: 33070664     DOI: 10.1161/HYPERTENSIONAHA.120.15527

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

Review 1.  Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations.

Authors:  Giovanna Gallo; Massimo Volpe; Speranza Rubattu
Journal:  Vasc Health Risk Manag       Date:  2022-07-11

Review 2.  Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.

Authors:  Carmine Savoia; Massimo Volpe; Reinhold Kreutz
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

Review 3.  Mechanical dependency of the SARS-CoV-2 virus and the renin-angiotensin-aldosterone (RAAS) axis: a possible new threat.

Authors:  Rohit Sen; Devashish Sengupta; Avinaba Mukherjee
Journal:  Environ Sci Pollut Res Int       Date:  2021-12-02       Impact factor: 5.190

Review 4.  Hypertension and COVID-19: Current Evidence and Perspectives.

Authors:  Giovanna Gallo; Valentin Calvez; Carmine Savoia
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-02-20

Review 5.  Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications.

Authors:  Giovanna Gallo; Massimo Volpe; Carmine Savoia
Journal:  Front Med (Lausanne)       Date:  2022-01-20

6.  Walnut supplementation after fructose-rich diet is associated with a beneficial fatty acid ratio and increased ACE2 expression in the rat heart.

Authors:  Maja Bošković; Maja Živković; Goran Koricanac; Snezana Tepavcevic; Manja Zec; Jasmina Debeljak-Martacic; Aleksandra Stanković
Journal:  Front Physiol       Date:  2022-09-21       Impact factor: 4.755

7.  Vascular Effects of Low-Dose ACE2 Inhibitor MLN-4760-Benefit or Detriment in Essential Hypertension?

Authors:  Andrea Berenyiova; Iveta Bernatova; Anna Zemancikova; Magdalena Drobna; Martina Cebova; Samuel Golas; Peter Balis; Silvia Liskova; Zuzana Valaskova; Katarina Krskova; Stefan Zorad; Ezgi Dayar; Sona Cacanyiova
Journal:  Biomedicines       Date:  2021-12-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.